DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Dr. Lal Path Labs Ltd. — Acquisition (including agreement to acquire)-XBRL

NSE 2 hrs ago·19 Aug 2026, 1:04 pm

DR. LAL Path Labs

Dr. Lal Path Labs Ltd. has informed stock exchanges that it is entering into an agreement to acquire another entity. The company has filed an XBRL report detailing this proposed transaction, which signals a strategic move to expand its business footprint.

For investors, this development indicates that the diagnostic major is looking to grow through acquisition rather than organic means. Such moves can potentially enhance market share and diversify the company's service offerings, which are generally viewed positively by the market.

Investors should keep an eye on the exchange filing for more specific details. Information regarding the size of the deal, the target company, and the timeline for completion will be crucial in determining the long-term impact on the stock.